Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
VTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the...